Annual CFF
$225.67 M
-$96.57 M-29.97%
December 31, 2023
Summary
- As of February 26, 2025, VRDN annual cash flow from financing activities is $225.67 million, with the most recent change of -$96.57 million (-29.97%) on December 31, 2023.
- During the last 3 years, VRDN annual CFF has risen by +$124.36 million (+122.75%).
- VRDN annual CFF is now -29.97% below its all-time high of $322.24 million, reached on December 31, 2022.
Performance
VRDN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$245.02 M
+$244.91 M+226773.15%
September 30, 2024
Summary
- As of February 26, 2025, VRDN quarterly cash flow from financing activities is $245.02 million, with the most recent change of +$244.91 million (+226773.15%) on September 30, 2024.
- Over the past year, VRDN quarterly CFF has increased by +$229.57 million (+1485.19%).
- VRDN quarterly CFF is now -15.78% below its all-time high of $290.93 million, reached on September 30, 2022.
Performance
VRDN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$621.15 M
+$229.57 M+58.62%
September 30, 2024
Summary
- As of February 26, 2025, VRDN TTM cash flow from financing activities is $621.15 million, with the most recent change of +$229.57 million (+58.62%) on September 30, 2024.
- Over the past year, VRDN TTM CFF has increased by +$568.41 million (+1077.70%).
- VRDN TTM CFF is now at all-time high.
Performance
VRDN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VRDN Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.0% | +1485.2% | +1077.7% |
| 3 y3 years | +122.8% | +1485.2% | +1077.7% |
| 5 y5 years | +438.4% | +1485.2% | +1077.7% |
VRDN Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -30.0% | +80.1% | -15.8% | >+9999.0% | at high | +1077.7% |
| 5 y | 5-year | -30.0% | >+9999.0% | -15.8% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -30.0% | >+9999.0% | -15.8% | >+9999.0% | at high | >+9999.0% |
Viridian Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $245.02 M(>+9900.0%) | $621.15 M(+58.6%) |
| Jun 2024 | - | $108.00 K(-99.9%) | $391.59 M(-0.8%) |
| Mar 2024 | - | $177.08 M(-11.0%) | $394.55 M(+74.8%) |
| Dec 2023 | $225.67 M(-30.0%) | $198.94 M(+1187.1%) | $225.67 M(+327.9%) |
| Sep 2023 | - | $15.46 M(+403.8%) | $52.74 M(-83.9%) |
| Jun 2023 | - | $3.07 M(-62.6%) | $328.22 M(-0.5%) |
| Mar 2023 | - | $8.20 M(-68.5%) | $329.71 M(+2.3%) |
| Dec 2022 | $322.24 M(+157.2%) | $26.01 M(-91.1%) | $322.24 M(+8.7%) |
| Sep 2022 | - | $290.93 M(+6282.9%) | $296.40 M(+142.4%) |
| Jun 2022 | - | $4.56 M(+517.6%) | $122.26 M(-2.0%) |
| Mar 2022 | - | $738.00 K(+334.1%) | $124.75 M(-0.4%) |
| Dec 2021 | $125.28 M(+23.7%) | $170.00 K(-99.9%) | $125.28 M(-38.2%) |
| Sep 2021 | - | $116.79 M(+1556.2%) | $202.79 M(+123.7%) |
| Jun 2021 | - | $7.05 M(+460.1%) | $90.64 M(+6.8%) |
| Mar 2021 | - | $1.26 M(-98.4%) | $84.86 M(-16.2%) |
| Dec 2020 | $101.31 M(>+9900.0%) | $77.68 M(+1572.4%) | $101.31 M(+314.8%) |
| Sep 2020 | - | $4.64 M(+266.3%) | $24.42 M(+29.4%) |
| Jun 2020 | - | $1.27 M(-92.8%) | $18.87 M(+7.4%) |
| Mar 2020 | - | $17.71 M(+2128.3%) | $17.57 M(>+9900.0%) |
| Dec 2019 | $70.00 K(-99.8%) | $795.00 K(-187.9%) | $70.00 K(-109.5%) |
| Sep 2019 | - | -$904.00 K(+2217.9%) | -$735.00 K(-157.3%) |
| Jun 2019 | - | -$39.00 K(-117.9%) | $1.28 M(-68.1%) |
| Mar 2019 | - | $218.00 K(-2280.0%) | $4.02 M(-90.4%) |
| Dec 2018 | $41.92 M | -$10.00 K(-100.9%) | $41.92 M(-22.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $1.11 M(-58.7%) | $53.84 M(-2.0%) |
| Jun 2018 | - | $2.70 M(-92.9%) | $54.92 M(+6.7%) |
| Mar 2018 | - | $38.11 M(+219.9%) | $51.47 M(-1.9%) |
| Dec 2017 | $52.47 M(<-9900.0%) | $11.91 M(+442.5%) | $52.47 M(+29.8%) |
| Sep 2017 | - | $2.20 M(-390.9%) | $40.42 M(+5.8%) |
| Jun 2017 | - | -$755.00 K(-101.9%) | $38.20 M(-1.8%) |
| Mar 2017 | - | $39.12 M(<-9900.0%) | $38.91 M(<-9900.0%) |
| Dec 2016 | -$257.00 K(-102.0%) | -$133.00 K(+411.5%) | -$257.00 K(+173.4%) |
| Sep 2016 | - | -$26.00 K(-49.0%) | -$94.00 K(-102.4%) |
| Jun 2016 | - | -$51.00 K(+8.5%) | $3.92 M(+16.7%) |
| Mar 2016 | - | -$47.00 K(-256.7%) | $3.36 M(-73.6%) |
| Dec 2015 | $12.71 M(+71.8%) | $30.00 K(-99.2%) | $12.71 M(+0.3%) |
| Sep 2015 | - | $3.98 M(-753.1%) | $12.66 M(+54.2%) |
| Jun 2015 | - | -$610.00 K(-106.6%) | $8.21 M(-51.4%) |
| Mar 2015 | - | $9.30 M(<-9900.0%) | $16.89 M(+128.3%) |
| Dec 2014 | $7.40 M(+487.5%) | -$11.00 K(-97.6%) | $7.40 M(-4.6%) |
| Sep 2014 | - | -$468.00 K(-105.8%) | $7.75 M(-8.8%) |
| Jun 2014 | - | $8.06 M(-4367.2%) | $8.50 M(+1259.1%) |
| Mar 2014 | - | -$189.00 K(-155.0%) | $625.20 K(-50.3%) |
| Dec 2013 | $1.26 M(-78.3%) | $343.40 K(+23.7%) | $1.26 M(+37.5%) |
| Sep 2013 | - | $277.50 K(+43.6%) | $915.60 K(+43.5%) |
| Jun 2013 | - | $193.30 K(-56.5%) | $638.10 K(+43.5%) |
| Mar 2013 | - | $444.80 K | $444.80 K |
| Dec 2012 | $5.81 M | - | - |
FAQ
- What is Viridian Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Viridian Therapeutics?
- What is Viridian Therapeutics annual CFF year-on-year change?
- What is Viridian Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Viridian Therapeutics?
- What is Viridian Therapeutics quarterly CFF year-on-year change?
- What is Viridian Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Viridian Therapeutics?
- What is Viridian Therapeutics TTM CFF year-on-year change?
What is Viridian Therapeutics annual cash flow from financing activities?
The current annual CFF of VRDN is $225.67 M
What is the all time high annual CFF for Viridian Therapeutics?
Viridian Therapeutics all-time high annual cash flow from financing activities is $322.24 M
What is Viridian Therapeutics annual CFF year-on-year change?
Over the past year, VRDN annual cash flow from financing activities has changed by -$96.57 M (-29.97%)
What is Viridian Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VRDN is $245.02 M
What is the all time high quarterly CFF for Viridian Therapeutics?
Viridian Therapeutics all-time high quarterly cash flow from financing activities is $290.93 M
What is Viridian Therapeutics quarterly CFF year-on-year change?
Over the past year, VRDN quarterly cash flow from financing activities has changed by +$229.57 M (+1485.19%)
What is Viridian Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VRDN is $621.15 M
What is the all time high TTM CFF for Viridian Therapeutics?
Viridian Therapeutics all-time high TTM cash flow from financing activities is $621.15 M
What is Viridian Therapeutics TTM CFF year-on-year change?
Over the past year, VRDN TTM cash flow from financing activities has changed by +$568.41 M (+1077.70%)